Epigral Limited to Consider Q2 FY27 Results on November 2

Epigral Limited is scheduled to consider its un-audited standalone and consolidated financial results for Q2 FY27 and the first half ended September 30, 2026, on November 2. The results will follow a June-quarter performance in which revenue reached ₹705 crore, while reported profit declined 37.9% despite sales growth of 16.3%.

When will Epigral announce its Q2 FY27 results?

Epigral's board of directors is scheduled to meet on Monday, November 2, 2026, to consider and approve the company's un-audited financial results for the quarter and half year ended September 30, 2026. The board-meeting intimation was filed with the exchanges on October 26 under the listing regulations.

The company had not filed the Q2 FY27 figures at the time of the announcement. As a result, the November 2 board meeting is the key disclosed event for investors awaiting the company's quarterly revenue, operating performance and profitability data for the July-September period.

The filing covers both standalone and consolidated results. It does not disclose any preliminary financial estimates, management outlook, dividend proposal or other operating update. Investors will therefore have to rely on the formal results announcement for the company's reported Q2 numbers.

What will happen during Epigral's investor conference call?

Epigral has scheduled an investor and analyst conference call at 5:00 p.m. IST on November 2 to discuss the Q2 FY27 results. The company disclosed the call through a Regulation 30 announcement dated October 28, with EMKAY Global providing the dial-in access.

The announced participants include Chairman Maulik Patel, Executive Director Kaushal Soparkar, Chief Financial Officer Rakesh Agrawal and investor relations head Milind Kotecha. The call gives investors and analysts an opportunity to hear management's discussion after the results are considered by the board.

The company has not disclosed the topics that management will address during the call. However, the event is specifically intended to discuss Q2 FY27 results, making the published financial statements and management commentary the main official sources of information for the quarter.

How did Epigral perform in the previous reported quarter?

Epigral reported revenue of ₹705 crore in the quarter ended June 2026, compared with ₹587 crore in September 2025, ₹597 crore in December 2025 and ₹736 crore in March 2026. The supplied quarterly data also shows operating profit of ₹136 crore in June 2026, the highest figure among those four reported quarters.

The June-quarter update stated that sales rose 16.3%, while profit fell 37.9%. This contrast makes the next result relevant because it will show whether revenue growth and operating profitability moved together in the September quarter. The source material does not provide the absolute profit figure for June 2026 or the basis of comparison for the reported percentage changes.

The March-to-June revenue movement was lower by ₹31 crore, while operating profit increased by ₹9 crore over the same period. These are reported quarterly figures and do not establish a trend for Q2 FY27, for which the company had not released financial data before the board meeting.

Why are the Q2 FY27 results important for investors?

The Q2 FY27 announcement will provide the first official view of Epigral's performance for the July-September period and a cumulative picture for the first six months of FY27. For shareholders, the release will add reported revenue, operating profit and profit data to the information available from the June quarter.

The company's recent disclosures also show its compliance process around unpublished price-sensitive information. Epigral closed its trading window for insiders from October 1, 2026, until 48 hours after the declaration of the un-audited Q2 results. The restriction was stated to be enforced through Central Depository Service Limited under SEBI regulations.

The timing of the board meeting and conference call concentrates attention on the same day. The results filing will provide the formal financial record, while the management call is expected to offer context around those figures. Neither the board-meeting notice nor the conference-call intimation includes a forecast for revenue, margins, profit or future operations.

Conclusion

Epigral's November 2 board meeting and subsequent conference call are the company's disclosed milestones for Q2 FY27. The prior quarter recorded ₹705 crore in revenue and ₹136 crore in operating profit, while the reported 16.3% sales increase was accompanied by a 37.9% decline in profit.

Investors will watch for the un-audited standalone and consolidated results for the quarter and half year ended September 30, 2026, followed by management's comments at the 5:00 p.m. IST conference call. The company has not released Q2 figures or a financial outlook ahead of these events.